132

SHORT- AND LONG-TERM OUTCOMES FOLLOWING BIOLOGIC USE BEFORE NON-CONVENTIONAL STRICUREPLASTY FOR CROHN’S JEJUNOILEITIS

Date
May 18, 2024
Explore related products in the following collection:

Background
Non-conventional strictureplasties, specifically the Finney and Michelassi techniques, are bowel-preserving surgeries for treating diffuse jejunoileal Crohn’s Disease (CD). We investigated the use of biologics during non-conventional strictureplasty for Crohn’s jejunoileitis and the association with short- and long-term outcomes.

Methods
We conducted a retrospective review of all patients with CD who underwent non-conventional strictureplasty at our center, such as side-to-side antiperistaltic strictureplasty (SSAS) according to the Finney technique, and side-to-side isoperistaltic strictureplasty (SSIS) according to the Michelassi technique, from January 2000 to October 2022. Patients were categorized into BIO and NoBIO groups based on whether they were treated with biologics at the time of surgery or not. Our outcomes of interest were: (a) 30-day complications; (b) surgical recurrence. Statistical analysis was performed using R version 4.3.1.

Results
A total of 71 patients underwent non-conventional strictureplasty: 80 SSAS and 14 SSIS. In the BIO group, 17 (24%) patients underwent surgery, with 15 receiving SSAS and 3 receiving SSIS Most patients (69%) also underwent a concurrent Heineke-Mikulicz strictureplasty or a concurrent small bowel resection (74.6%). The patients in the BIO and NoBIO groups had similar baseline characteristics (Table 1). No difference was observed when comparing surgical recurrence rates (rate 52.9% vs. rate 48.1%, p=0.95), but a longer median time to recurrence was observed in the BIO group (4.7 vs. 4.4 years, p=0.004). (Table 2).

Conclusion
The use of biologics at the time of non-conventional strictureplasty for diffuse jejunoileal Crohn’s disease appears to be safe and is associated with a longer median time to recurrence.

Tracks

Related Products

Thumbnail for ONCOLOGIC OUTCOMES AFTER POUCH EXCISION: IS THERE A DIFFERENCE BETWEEN IBD AND FAP POUCH NEOPLASIA?
ONCOLOGIC OUTCOMES AFTER POUCH EXCISION: IS THERE A DIFFERENCE BETWEEN IBD AND FAP POUCH NEOPLASIA?
Ileoanal pouch patients are at risk of neoplasia of the rectal cuff/anal transitional zone (ATZ) and the pouch, but it is unknown whether underlying diagnosis that impacted pouch construction affects oncologic outcomes after pouch excision…
Thumbnail for MALE GENITOURINARY DYSFUNCTION AFTER MINIMALLY INVASIVE AND OPEN ILEOANAL POUCH
MALE GENITOURINARY DYSFUNCTION AFTER MINIMALLY INVASIVE AND OPEN ILEOANAL POUCH
Restorative proctocolectomy with ileal pouch-anal anastomosis (IPAA) is the preferred surgical treatment for IBD or FAP. As these diseases often manifest during adolescence or early adulthood, treatment effects on genitourinary function (GU), sexual function, and fertility are clinically important…
Thumbnail for HEALING OF PERINEAL WOUNDS AFTER PROCTECTOMY FOR CROHN'S DISEASE: A SYSTEMATIC REVIEW AND META-ANALYSIS
HEALING OF PERINEAL WOUNDS AFTER PROCTECTOMY FOR CROHN'S DISEASE: A SYSTEMATIC REVIEW AND META-ANALYSIS
BACKGROUND: Non-healing perineal wounds are common in patients undergoing proctectomy for Crohn’s disease. We systematically reviewed the literature and performed a meta-analysis to estimate the pooled proportion of perineal wound healing after proctectomy for Crohn’s disease…
Thumbnail for MALE GENITOURINARY DYSFUNCTION AFTER PRIMARY AND REOPERATIVE ILEONAL POUCH SURGERY
MALE GENITOURINARY DYSFUNCTION AFTER PRIMARY AND REOPERATIVE ILEONAL POUCH SURGERY
Restorative proctocolectomy with ileal pouch-anal anastomosis (IPAA) is the preferred surgical treatment for patients with IBD or FAP…